Analyst Expect Big Moves From Disc Medicine Inc (NASDAQ: IRON)

Currently, there are 24.68M common shares owned by the public and among those 12.58M shares have been available to trade.

The company’s stock has a 5-day price change of -43.56% and -39.96% over the past three months. IRON shares are trading -40.77% year to date (YTD), with the 12-month market performance up to 57.43% higher. It has a 12-month low price of $18.25 and touched a high of $77.60 over the same period. IRON has an average intraday trading volume of 292.19K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -47.17%, -47.76%, and -37.73% respectively.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Institutional ownership of Disc Medicine Inc (NASDAQ: IRON) shares accounts for 51.88% of the company’s 24.68M shares outstanding.

It has a market capitalization of $844.30M and a beta (3y monthly) value of 0.17. The earnings-per-share (ttm) stands at -$3.50. Price movements for the stock have been influenced by the stock’s volatility, which stands at 11.13% over the week and 8.18% over the month.

Analysts forecast that Disc Medicine Inc (IRON) will achieve an EPS of -$1.02 for the current quarter, -$1.05 for the next quarter and -$5.32 for 2025. The lowest estimate earnings-per-share for the quarter is -$1.22 while analysts give the company a high EPS estimate of -$0.76. Comparatively, EPS for the current quarter was -$1.2 a year ago. Earnings per share for the fiscal year are expected to decrease by -27.48%, and -20.18% over the next financial year.

Looking at the support for the IRON, a number of firms have released research notes about the stock. Raymond James stated their Outperform rating for the stock in a research note on Apr-02-24, with the firm’s price target at $40. Morgan Stanley coverage for the Disc Medicine Inc (IRON) stock in a research note released on December 19, 2023 offered a Equal-Weight rating with a price target of $65. Raymond James was of a view on June 09, 2023 that the stock is Strong Buy, while H.C. Wainwright gave the stock Buy rating on June 07, 2023, issuing a price target of $55. Raymond James on their part issued Outperform rating on May 17, 2023.

Most Popular

Related Posts